About this Research Topic
Aberrant cellular metabolisms have been known to play a crucial role in the initiation, progression, metastasis, and chemoresistance of hematologic malignancies over the years. Dysregulation of mitochondria metabolism increases the production of reactive oxygen species (ROS), thereby triggering aging in hematopoietic cells and subsequent cellular aberrations. Over the past few years, therapeutic strategies targeting mitochondria metabolisms have shown some benefits in improving the clinical efficacy of hematologic malignancy. However, there are still many unanswered questions and challenges that need to be addressed, such as molecular mechanisms involved, novel targets with mitochondria metabolism, novel chemical and molecular compounds targeting cellular metabolism, and the role of metabolism dysregulation in clonal evolution and epigenetics in hematologic malignancies.
This research topic endeavors to provide audiences with the latest insightful advancements in the field of metabolism dysregulation/reprogramming in hematologic malignancies. We welcome authors to submit Original Research, Review, and Case Reports articles with a primary focus on, but not limited to, the following subtopics.
● The pathogenesis and molecular mechanisms of hematologic malignancies in terms of metabolism dysregulations
● Clinical studies and preclinical studies targeting mitochondria metabolism
● Synergistic effect of metabolism inhibitors in the combination therapy of hematologic malignancies
● Development of novel molecular targets for mitochondrial metabolism in hematologic malignancies
● Novel chemical compounds targeting mitochondria metabolism for the treatment of hematologic malignancies
● Metabolism dysregulation in regulating clonal evolution, epigenetics in hematologic malignancies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
This research topic endeavors to provide audiences with the latest insightful advancements in the field of metabolism dysregulation/reprogramming in hematologic malignancies. We welcome authors to submit Original Research, Review, and Case Reports articles with a primary focus on, but not limited to, the following subtopics.
● The pathogenesis and molecular mechanisms of hematologic malignancies in terms of metabolism dysregulations
● Clinical studies and preclinical studies targeting mitochondria metabolism
● Synergistic effect of metabolism inhibitors in the combination therapy of hematologic malignancies
● Development of novel molecular targets for mitochondrial metabolism in hematologic malignancies
● Novel chemical compounds targeting mitochondria metabolism for the treatment of hematologic malignancies
● Metabolism dysregulation in regulating clonal evolution, epigenetics in hematologic malignancies
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: metabolism dysregulation/reprogramming, hematologic malignancies, therapeutic target, pathogenesis, drug synergy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
